22 September 2021
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
21 September 2021: Piscataway, New Jersey; Oxford and Manchester, UK; Mahwah, New Jersey. Today, Infinity BiologiX, LLC (IBX), Cytox Ltd, and Vanguard Pharma announce the launch of the IBX Alzheimer’s Risk Test, powered by genoSCORETM. Physicians are able to pre-register...
21 September 2021
New study launched to investigate targeted treatments for Schizophrenia
Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia. Currently, there are no treatments on the market for cognitive impairment...
20 September 2021
Boehringer Ingelheim and Oxford BioTherapeutics partnership advances second oncology drug candidate into the clinic
The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by Oxford BioTherapeutics’ proprietary OGAP® target discovery platform … Oxford, UK; Morristown New Jersey and San Jose, Calif., 20th September 2021 - Oxford...
6 September 2021
Maxwellia strengthens its Marketing team with two new appointments
Maxwellia, the UK’s only company 100% dedicated to switching Rx to OTC medicines has created two new senior roles in its marketing team. The team expansion follows the success of the recent landmark reclassification of the progestogen only pill by the MHRA, a change...
1 September 2021
Rinicare’s continuous vital signs monitoring technology deployed across hospitals and Covid-19 health centres in India
Rinicare’s continuous vital signs monitoring technology platform, PRIME™, has started to be distributed across hospitals, health centres, and Covid-19 centres in Maharashtra state, India’s second most populous state with a population of 114 million people. The...
27 August 2021
£2m funding boost for Infex’s work on pandemic preparedness
Infex Therapeutics, the Alderley Park-based biotech developing new clinical pipeline of innovative drugs to treat critical priority infectious diseases, has completed an interim funding round worth £2.1m to expand its coronavirus therapeutics portfolio. Supported by...
26 August 2021
Rinicare launches new AI-driven risk prediction solution for atrial fibrillation
The STABILITY platform uses AI technology to provide advanced clinical risk prediction, and acts as an early warning system for patient deterioration … Manchester-based MedTech start-up Rinicare has launched a new application for its ground-breaking clinical risk prediction...
25 August 2021
Viscgo completes £315k investment round
Manchester-based medical device company Viscgo has a completed a £315,000 investment round. The firm, based in Manchester Science Park, has been able to complete this due to a £50,000 investment from North West early-stage investor GC Angels. This comes following...
18 August 2021
Clin-e-Cal wins share of £4m tech fund to revolutionise asthma self-management
Asthma UK and British Lung Foundation has announced the winners of their £4 million asthma tech fund which aims to kick-start a revolution in asthma self-management. The research grants, created in partnership with the National Institute for Health Research (NIHR) and the...
11 August 2021
Panthera steps up its move into oncology trials with more than 12 trials in the pipeline and a prostate trial underway
Panthera has accelerated its move into running oncology trials – as part of its partnership with Rutherford Health plc – with an open label prostate cancer trial underway and 12 more trials in the pipeline. Panthera’s partnership with Rutherford not only...